Over the last 7 days, the United States market has remained flat, although it is up 20% over the past year, with earnings expected to grow by 17% per annum in the coming years. The term 'penny stocks' might feel like a relic of past market eras, but they continue to represent real potential for investors seeking affordability and growth when backed by strong financials. In this article, we will explore several penny stocks that stand out for their financial strength and potential for long-term success.

We'll examine a selection from our screener results.

Identiv (INVE)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Identiv, Inc. develops, manufactures, and supplies specialty IoT products across various regions including the United States, Europe, the Middle East, and Asia-Pacific with a market cap of $66.41 million.

Operations: The company generates revenue from its IoT Business segment, which amounted to $24.27 million.

Market Cap: $66.41M

Identiv, Inc., with a market cap of US$66.41 million, has shown potential in the penny stock segment through its diverse IoT product offerings. Despite being unprofitable and experiencing increased losses over the past five years, Identiv's revenue from its IoT Business segment reached US$24.27 million. The company maintains a strong cash position, with short-term assets significantly exceeding liabilities and no debt on its balance sheet. Recent developments include expanding their ID-Tiny product line for secure digital intelligence and announcing plans to sell their IoT business assets to Trackonomy Systems, which could impact future operations positively or negatively depending on execution.

SIGA Technologies (SIGA)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: SIGA Technologies, Inc. is a commercial-stage pharmaceutical company that focuses on the health security market in the United States, with a market cap of $210.52 million.

Operations: The company's revenue is primarily derived from its Pharmaceuticals segment, totaling $53.66 million.

Market Cap: $210.52M

SIGA Technologies, Inc., with a market cap of US$210.52 million, operates in the health security market and recently reported a decline in revenue to US$41 million for Q2 2026 from US$81.12 million a year ago. Despite being unprofitable, SIGA has no debt, and its short-term assets of US$170.4 million comfortably cover liabilities. The company is trading at a significant discount to estimated fair value and has not diluted shareholders recently. However, it was dropped from several growth indices but added to the Russell 2000 Value-Defensive Index, reflecting shifting investor sentiment towards defensive positioning.

Emergent BioSolutions (EBS)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Emergent BioSolutions Inc. is a life sciences company offering preparedness and response solutions for various public health threats globally, with a market cap of $230.73 million.

Operations: The company generates revenue through its MCM Products segment, which accounts for $511.5 million, and Commercial Products segment, contributing $208.6 million.

Market Cap: $230.73M

Emergent BioSolutions, with a market cap of US$230.73 million, faces significant challenges as it remains unprofitable with a negative return on equity of -51.79%. Despite this, the company maintains a cash runway exceeding three years and has secured substantial contracts, including recent agreements with the U.S. Department of Health and Human Services for its ACAM2000 vaccine and BAT antitoxin. However, Emergent's financial guidance was lowered for 2026 due to increased net losses and asset impairments totaling US$191.3 million in Q2 2026. The company's high debt levels also pose concerns amidst ongoing restructuring efforts to improve financial stability.

Turning Ideas Into Actions

• Navigate through the entire inventory of 322 US Penny Stocks here.
• Curious About Other Options? We've found 8 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.